vs $ 200−999 consumer platforms
$ 0.001 per analysis
replaces $ 30−45 in point solutions
PMPM
vs 5 in biometric screening
biomarkers
Clinical Evidence
Not marketing claims — published data, validated on real CDC patients. Tested across 5 AI models. Published on medRxiv, under peer review at JAMIA Open.
$0.001
Per Patient
10,000× cheaper than consumer
4 018
CDC Patients
NHANES 2017-2018 cohort
93.2%
Sensitivity
Catches 93 of 100 at-risk
0.963
F1 Score
Best across 5 models (Grok-3)
Book a 15-minute
discovery call
discovery call
We'll show you how Zenlo
maps to your claims data
maps to your claims data
Ready to See What Your
Blood Work Already Knows?
90-Day Pilot
Measurable ROI
No Lock-In
HIPAA-Ready Architecture
Anthropic BAA Signed
SOC 2 Target Q3 2026
Book a Slot via Calendly
© 2026 Zenlo. Los Angeles, CA. Not medical advice — wellness platform only.
The Solution
From Routine Blood Work to Early Detection
No new tests, no on-site clinics, no hardware. Zenlo turns existing lab results into actionable health intelligence.
26× cost gap → caught early
Targeted intervention — only those who need it get enrolled.
Zero individual PHI exposed
Employees get insights. Employers see aggregate risk only
PDF → 98 biomarkers parsed
Employees upload routine blood work — any lab PDF
F1 = 0.963 · 5 AI models
AI cross-references 98 biomarkers across 15 clinical patterns
The Solution
From Routine Blood Work to Early Detection
No new tests, no on-site clinics, no hardware. Zenlo turns existing lab results into actionable health intelligence.
26× cost gap → caught early
Targeted intervention — only those who need it get enrolled.
Zero individual PHI exposed
Employees get insights. Employers see aggregate risk only
PDF → 98 biomarkers parsed
Employees upload routine blood work — any lab PDF
F1 = 0.963 · 5 AI models
AI cross-references 98 biomarkers across 15 clinical patterns